In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In a Red-Hot Orthopedics Market, Zimmer buys Implex

Executive Summary

Zimmer's acquisition of Implex Corp. for slightly greater than $100 million is, in some respects, the natural culmination of a standing alliance between the two companies. But it's also interesting for the way in which it seems to embrace all of orthopedics' hot spots. Building on Implex's innovative Hedrocel biomaterial, Zimmer has already developed hip, knee, and shoulder implants, as well as trauma products, out of the collaboration, and has announced that seven development projects are underway. At the same time, this is also clearly a spine play: Implex had developed a line of spine products out of its material, which have already begun to be implanted in Europe and the US, and Zimmer said in announcing the deal that it intends to expand that spine business by incorporating it into Zimmer's own spine division.
Advertisement

Related Content

Navigating Ortho's Choppy Seas: An Interview with Zimmer's David Dvorak
Spine-Bending Market
Endius: Waiting for the Revolution in Spine
In Spine, a New Kind of Corporate Venturing
Big Device Deals Still Hot in Europe as Synthes Follows Zimmer and Geitinge Extends Its Reach
Smith & Nephew and Centerpulse: Perfect Together
Spine Arthroplasty's Next Generation
SpineVision: Meeting the Competition Head On
In Spine, A Flurry of Deals
Spinal Dynamics Sticks Its Neck Out

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002043

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel